Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2

Science Translational Medicine

Volumn 9, Issue 378, 2017, Pages

  Ler, Lian Dee ^a,b,c   Ghosh, Sujoy ^b   Chai, Xiaoran ^b   Thike, Aye Aye ^d   Heng, Hong Lee ^a,b   Siew, Ee Yan ^a,b   Dey, Sucharita ^e   Koh, Liang Kai ^a,b   Lim, Jing Quan ^a,b   Lim, Weng Khong ^a,b   Myint, Swe Swe ^a,b   Loh, Jia Liang ^a,b   Ong, Pauline ^a,b   Sam, Xin Xiu ^d   Huang, Dachuan ^a,b   Lim, Tony ^d   Tan, Puay Hoon ^d   Nagarajan, Sanjanaa ^a,b   Cheng, Christopher Wai Sam ^d   Ho, Henry ^d   Ng, Lay Guat ^d   Yuen, John ^d   Lin, Po Hung ^f   Chuang, Cheng Keng ^f   Chang, Ying Hsu ^f   Weng, Wen Hui ^g   Rozen, Steven G ^b   Tan, Patrick ^a,b,e,h   Creasy, Caretha L ⁱ   Pang, See Tong ^f   Mccabe, Michael T ⁱ   Poon, Song Ling ^a,b   Teh, Bin Tean ^a,b,e,j   more..

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f CHANG GUNG UNIVERSITY   (Taiwan)

^g NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^h GENOME INSTITUTE OF SINGAPORE   (Singapore)

ⁱ GLAXOSMITHKLINE   (United States)

^j INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE H3K27; POLYCOMB REPRESSIVE COMPLEX 2; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; HISTONE DEMETHYLASE; IGFBP3 PROTEIN, HUMAN; NUCLEAR PROTEIN; UTX PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; HUMAN; HUMAN TISSUE; IGFBP3 GENE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; KDM6A GENE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION RATE; NONHUMAN; NONSENSE MUTATION; PREVALENCE; PROTEIN DEPLETION; RNA SEQUENCE; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; UROTHELIUM;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEMETHYLASES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION, GENETIC; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 85014696661     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aai8312     Document Type: Article

References (73)

1. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015).
2. X.-R. Wu, Urothelial tumorigenesis: A tale of divergent pathways. Nat. Rev. Cancer 5, 713-725 (2005).
3. D. S. Kaufman, W. U. Shipley, A. S. Feldman, Bladder cancer. Lancet 374, 239-249 (2009).
4. S. M. Prasad, G. J. DeCastro, G. D. Steinberg, Urothelial carcinoma of the bladder: Definition, treatment and future efforts. Nat. Rev. Urol. 8, 631-642 (2011).
5. R. S. Svatek, B. K. Hollenbeck, S. Holmäng, R. Lee, S. P. Kim, A. Stenzl, Y. Lotan, The economics of bladder cancer: Costs and considerations of caring for this disease. Eur. Urol. 66, 253-262 (2014).
6. P. E. Clark, N. Agarwal, M. C. Biagioli, M. A. Eisenberger, R. E. Greenberg, H. W. Herr, B. A. Inman, D. A. Kuban, T. M. Kuzel, S. M. Lele, J. Michalski, L. C. Pagliaro, S. K. Pal, A. Patterson, E. R. Plimack, K. S. Pohar, M. P. Porter, J. P. Richie, W. J. Sexton, W. U. Shipley, E. J. Small, P. E. Spiess, D. L. Trump, G. Wile, T. G. Wilson, M. Dwyer, M. Ho; National Comprehensive Cancer Network (NCCN), Bladder cancer. J. Natl. Compr. Canc. Netw. 11, 446-475 (2013).
7. Z. L. Zhang, P. Dong, Y. H. Li, Z. W. Liu, K. Yao, H. Han, Z. K. Qin, F. J. Zhou, Radical cystectomy for bladder cancer: Oncologic outcome in 271 Chinese patients. Chin. J. Cancer 33, 165-171 (2014).
8. J. E. Rosenberg, J. Hoffman-Censits, T. Powles, M. S. van der Heijden, A. V. Balar, A. Necchi, N. Dawson, P. H. O'Donnell, A. Balmanoukian, Y. Loriot, S. Srinivas, M. M. Retz, P. Grivas, R. W. Joseph, M. D. Galsky, M. T. Fleming, D. P. Petrylak, J. L. Perez-Gracia, H. A. Burris, D. Castellano, C. Canil, J. Bellmunt, D. Bajorin, D. Nickles, R. Bourgon, G. M. Frampton, N. Cui, S. Mariathasan, O. Abidoye, G. D. Fine, R. Dreicer, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-Arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016).
9. Cancer Genome Atlas Research Network, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
10. Y. Gui, G. Guo, Y. Huang, X. Hu, A. Tang, S. Gao, R. Wu, C. Chen, X. Li, L. Zhou, M. He, Z. Li, X. Sun, W. Jia, J. Chen, S. Yang, F. Zhou, X. Zhao, S. Wan, R. Ye, C. Liang, Z. Liu, P. Huang, C. Liu, H. Jiang, Y. Wang, H. Zheng, L. Sun, X. Liu, Z. Jiang, D. Feng, J. Chen, S. Wu, J. Zou, Z. Zhang, R. Yang, J. Zhao, C. Xu, W. Yin, Z. Guan, J. Ye, H. Zhang, J. Li, K. Kristiansen, M. L. Nickerson, D. Theodorescu, Y. Li, X. Zhang, S. Li, J. Wang, H. Yang, J. Wang, Z. Cai, Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875-878 (2011).
11. J. S. Ross, K. Wang, R. N. Al-Rohil, T. Nazeer, C. E. Sheehan, G. A. Otto, J. He, G. Palmer, R. Yelensky, D. Lipson, S. Ali, S. Balasubramanian, J. A. Curran, L. Garcia, K. Mahoney, S. R. Downing, M. Hawryluk, V. A. Miller, P. J. Stephens, Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. 27, 271-280 (2014).
12. G. van Haaften, G. L. Dalgliesh, H. Davies, L. Chen, G. Bignell, C. Greenman, S. Edkins, C. Hardy, S. O'Meara, J. Teague, A. Butler, J. Hinton, C. Latimer, J. Andrews, S. Barthorpe, D. Beare, G. Buck, P. J. Campbell, J. Cole, S. Forbes, M. Jia, D. Jones, C. Y. Kok, C. Leroy, M. L. Lin, D. J. McBride, M. Maddison, S. Maquire, K. McLay, A. Menzies, T. Mironenko, L. Mulderrig, L. Mudie, E. Pleasance, R. Shepherd, R. Smith, L. Stebbings, P. Stephens, G. Tang, P. S. Tarpey, R. Turner, K. Turrell, J. Varian, S. West, S. Widaa, P. Wray, V. P. Collins, K. Ichimura, S. Law, J. Wong, S. T. Yuen, S. Y. Leung, G. Tonon, R. A. DePinho, Y.-T. Tai, K. C. Anderson, R. J. Kahnoski, A. Massie, S. K. Khoo, B. T. Teh, M. R. Stratton, P. A. Futreal, Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
13. M. S. Lawrence, P. Stojanov, C. H. Mermel, J. T. Robinson, L. A. Garraway, T. R. Golub, M. Meyerson, S. B. Gabriel, E. S. Lander, G. Getz, Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
14. I. Nordentoft, P. Lamy, K. Birkenkamp-Demtröder, K. Shumansky, S. Vang, H. Hornshøj, M. Juul, P. Villesen, J. Hedegaard, A. Roth, K. Thorsen, S. Høyer, M. Borre, T. Reinert, N. Fristrup, L. Dyrskjøt, S. Shah, J. S. Pedersen, T. F. Ørntoft, Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 7, 1649-1663 (2014).
15. G. M. Dancik, C. R. Owens, K. A. Iczkowski, D. Theodorescu, A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells 32, 974-982 (2014).
16. S. L. Poon, S.-T. Pang, J. R. McPherson, W. Yu, K. K. Huang, P. Guan, W.-H. Weng, E. Y. Siew, Y. Liu, H. L. Heng, S. C. Chong, A. Gan, S. T. Tay, W. K. Lim, I. Cutcutache, D. Huang, L. D. Ler, M.-L. Nairismägi, M. H. Lee, Y.-H. Chang, K.-J. Yu, W. Chan-on, B.-K. Li, Y.-F. Yuan, C.-N. Qian, K.-F. Ng, C.-F. Wu, C.-L. Hsu, R. M. Bunte, M. R. Stratton, P. A. Futreal, W.-K. Sung, C.-K. Chuang, C. K. Ong, S. G. Rozen, P. Tan, B. T. Teh, Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 5, 197ra101 (2013).
17. K. Agger, P. A. Cloos, J. Christensen, D. Pasini, S. Rose, J. Rappsilber, I. Issaeva, E. Canaani, A. E. Salcini, K. Helin, UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731-734 (2007).
18. M. G. Lee, R. Villa, P. Trojer, J. Norman, K.-P. Yan, D. Reinberg, L. Di Croce, R. Shiekhattar, Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318, 447-450 (2007).
19. Y.-W. Cho, T. Hong, S. Hong, H. Guo, H. Yu, D. Kim, T. Guszczynski, G. R. Dressler, T. D. Copeland, M. Kalkum, K. Ge, PTIP associates with MLL3-And MLL4-containing histone H3 lysine 4 methyltransferase complex. J. Biol. Chem. 282, 20395-20406 (2007).
20. I. Issaeva, Y. Zonis, T. Rozovskaia, K. Orlovsky, C. M. Croce, T. Nakamura, A. Mazo, L. Eisenbach, E. Canaani, Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol. Cell. Biol. 27, 1889-1903 (2007).
21. C. Balbás-Martinez, A. Sagrera, E. Carrillo-de-Santa-Pau, J. Earl, M. Marquez, M. Vazquez, E. Lapi, F. Castro-Giner, S. Beltran, M. Bayes, A. Carrato, J. C. Cigudosa, O. Dominguez, M. Gut, J. Herranz, N. Juanpere, M. Kogevinas, X. Langa, E. López-Knowles, J. A. Lorente, J. Lloreta, D. G. Pisano, L. Richart, D. Rico, R. N. Salgado, A. Tardón, S. Chanock, S. Heath, A. Valencia, A. Losada, I. Gut, N. Malats, F. X. Real, Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat. Genet. 45, 1464-1469 (2013).
22. G. Guo, X. Sun, C. Chen, S. Wu, P. Huang, Z. Li, M. Dean, Y. Huang, W. Jia, Q. Zhou, A. Tang, Z. Yang, X. Li, P. Song, X. Zhao, R. Ye, S. Zhang, Z. Lin, M. Qi, S. Wan, L. Xie, F. Fan, M. L. Nickerson, X. Zou, X. Hu, L. Xing, Z. Lv, H. Mei, S. Gao, C. Liang, Z. Gao, J. Lu, Y. Yu, C. Liu, L. Li, X. Fang, Z. Jiang, J. Yang, C. Li, X. Zhao, J. Chen, F. Zhang, Y. Lai, Z. Lin, F. Zhou, H. Chen, H. C. Chan, S. Tsang, D. Theodorescu, Y. Li, X. Zhang, J. Wang, H. Yang, Y. Gui, J. Wang, Z. Cai, Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45, 1459-1463 (2013).
23. T. Sengoku, S. Yokoyama, Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. Genes Dev. 25, 2266-2277 (2011).
24. S. Hong, Y. W. Cho, L. R. Yu, H. Yu, T. D. Veenstra, K. Ge, Identification of JmjC domaincontaining UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl. Acad. Sci. U.S.A. 104, 18439-18444 (2007).
25. F. Lan, P. E. Bayliss, J. L. Rinn, J. R. Whetstine, J. K. Wang, S. Chen, S. Iwase, R. Alpatov, I. Issaeva, E. Canaani, T. M. Roberts, H. Y. Chang, Y. Shi, A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 449, 689-694 (2007).
26. M. R. Hubner, D. L. Spector, Role of H3K27 demethylases Jmjd3 and UTX in transcriptional regulation. Cold Spring Harb. Symp. Quant. Biol. 75, 43-49 (2010).
27. S. K. Verma, X. Tian, L. V. LaFrance, C. Duquenne, D. P. Suarez, K. A. Newlander, S. P. Romeril, J. L. Burgess, S. W. Grant, J. A. Brackley, A. P. Graves, D. A. Scherzer, A. Shu, C. Thompson, H. M. Ott, G. S. Aller, C. A. Machutta, E. Diaz, Y. Jiang, N. W. Johnson, S. D. Knight, R. G. Kruger, M. T. McCabe, D. Dhanak, P. J. Tummino, C. L. Creasy, W. H. Miller, Identification of potent, selective, cell-Active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3, 1091-1096 (2012).
28. W. Béguelin, R. Popovic, M. Teater, Y. Jiang, K. L. Bunting, M. Rosen, H. Shen, S. N. Yang, L. Wang, T. Ezponda, E. Martinez-Garcia, H. Zhang, Y. Zheng, S. K. Verma, M. T. McCabe, H. M. Ott, G. S. Van Aller, R. G. Kruger, Y. Liu, C. F. McHugh, D. W. Scott, Y. R. Chung, N. Kelleher, R. Shaknovich, C. L. Creasy, R. D. Gascoyne, K.-K. Wong, L. Cerchietti, R. L. Levine, O. Abdel-Wahab, J. D. Licht, O. Elemento, A. M. Melnick, EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013).
29. F. Christoph, S. Weikert, C. Kempkensteffen, H. Krause, M. Schostak, K. Miller, M. Schrader, Regularly methylated novel pro-Apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int. J. Cancer 119, 1396-1402 (2006).
30. C. Wang, J. E. Lee, Y. W. Cho, Y. Xiao, Q. Jin, C. Liu, K. Ge, UTX regulates mesoderm differentiation of embryonic stem cells independent of H3K27 demethylase activity. Proc. Natl. Acad. Sci. U.S.A. 109, 15324-15329 (2012).
31. R. C. Baxter, IGF binding proteins in cancer: Mechanistic and clinical insights. Nat. Rev. Cancer 14, 329-341 (2014).
32. H. Zhao, H. B. Grossman, M. R. Spitz, S. P. Lerner, K. Zhang, X. Wu, Plasma levels of insulinlike growth factor-1 and binding protein-3, and their association with bladder cancer risk. J. Urol. 169, 714-717 (2003).
33. A. Sparmann, M. van Lohuizen, Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6, 846-856 (2006).
34. S. K. Knutson, T. J. Wigle, N. M. Warholic, C. J. Sneeringer, C. J. Allain, C. R. Klaus, J. D. Sacks, A. Raimondi, C. R. Majer, J. Song, M. P. Scott, L. Jin, J. J. Smith, E. J. Olhava, R. Chesworth, M. P. Moyer, V. M. Richon, R. A. Copeland, H. Keilhack, R. M. Pollock, K. W. Kuntz, A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
35. M. T. McCabe, H. M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G. S. V. Aller, Y. Liu, A. P. Graves, A. D. Pietra III, E. Diaz, L. V. LaFrance, M. Mellinger, C. Duquenne, X. Tian, R. G. Kruger, C. F. McHugh, M. Brandt, W. H. Miller, D. Dhanak, S. K. Verma, P. J. Tummino, C. L. Creasy, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 492, 108-112 (2012).
36. W. Qi, H. Chan, L. Teng, L. Li, S. Chuai, R. Zhang, J. Zeng, M. Li, H. Fan, Y. Lin, J. Gu, O. Ardayfio, J.-H. Zhang, X. Yan, J. Fang, Y. Mi, M. Zhang, T. Zhou, G. Feng, Z. Chen, G. Li, T. Yang, K. Zhao, X. Liu, Z. Yu, C. X. Lu, P. Atadja, E. Li, Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. U.S.A. 109, 21360-21365 (2012).
37. J. Ahn, K. H. Kim, S. Park, Y.-H. Ahn, H. Y. Kim, H. Yoon, J. H. Lee, D. Bang, D. H. Lee, Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer. Oncotarget 7, 63252-63260 (2016).
38. L. J. Walport, R. J. Hopkinson, M. Vollmar, S. K. Madden, C. Gileadi, U. Oppermann, C. J. Schofield, C. Johansson, Human UTY(KDM6C) is a male-specific ND-methyl lysyl demethylase. J. Biol. Chem. 289, 18302-18313 (2014).
39. E. L. Greer, Y. Shi, Histone methylation: A dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13, 343-357 (2012).
40. B. G. Wilson, X. Wang, X. Shen, E. S. McKenna, M. E. Lemieux, Y.-J. Cho, E. C. Koellhoffer, S. L. Pomeroy, S. H. Orkin, C. W. M. Roberts, Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18, 316-328 (2010).
41. L. M. LaFave, W. Béguelin, R. Koche, M. Teater, B. Spitzer, A. Chramiec, E. Papalexi, M. D. Keller, T. Hricik, K. Konstantinoff, J.-B. Micol, B. Durham, S. K. Knutson, J. E. Campbell, G. Blum, X. Shi, E. H. Doud, A. V. Krivtsov, Y. R. Chung, I. Khodos, E. de Stanchina, O. Ouerfelli, P. S. Adusumilli, P. M. Thomas, N. L. Kelleher, M. Luo, H. Keilhack, O. Abdel-Wahab, A. Melnick, S. A. Armstrong, R. L. Levine, Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21, 1344-1349 (2015).
42. K. H. Kim, W. Kim, T. P. Howard, F. Vazquez, A. Tsherniak, J. N. Wu, W. Wang, J. R. Haswell, L. D. Walensky, W. C. Hahn, S. H. Orkin, C. W. M. Roberts, SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21, 1491-1496 (2015).
43. A. S. Ho, K. Kannan, D. M. Roy, L. G. T. Morris, I. Ganly, N. Katabi, D. Ramaswami, L. A. Walsh, S. Eng, J. T. Huse, J. Zhang, I. Dolgalev, K. Huberman, A. Heguy, A. Viale, M. Drobnjak, M. A. Leversha, C. E. Rice, B. Singh, N. G. Iyer, C. R. Leemans, E. Bloemena, R. L. Ferris, R. R. Seethala, B. E. Gross, Y. Liang, R. Sinha, L. Peng, B. J. Raphael, S. Turcan, Y. Gong, N. Schultz, S. Kim, S. Chiosea, J. P. Shah, C. Sander, W. Lee, T. A. Chan, The mutational landscape of adenoid cystic carcinoma. Nat. Genet. 45, 791-798 (2013).
44. J. Van der Meulen, F. Speleman, P. Van Vlierberghe, The H3K27me3 demethylase UTX in normal development and disease. Epigenetics 9, 658-668 (2014).
45. G. Robinson, M. Parker, T. A. Kranenburg, C. Lu, X. Chen, L. Ding, T. N. Phoenix, E. Hedlund, L. Wei, X. Zhu, N. Chalhoub, S. J. Baker, R. Huether, R. Kriwacki, N. Curley, R. Thiruvenkatam, J. Wang, G. Wu, M. Rusch, X. Hong, J. Becksfort, P. Gupta, J. Ma, J. Easton, B. Vadodaria, A. Onar-Thomas, T. Lin, S. Li, S. Pounds, S. Paugh, D. Zhao, D. Kawauchi, M. F. Roussel, D. Finkelstein, D. W. Ellison, C. C. Lau, E. Bouffet, T. Hassall, S. Gururangan, R. Cohn, R. S. Fulton, L. L. Fulton, D. J. Dooling, K. Ochoa, A. Gajjar, E. R. Mardis, R. K. Wilson, J. R. Downing, J. Zhang, R. J. Gilbertson, Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48 (2012).
46. N. Waddell, M. Pajic, A.-M. Patch, D. K. Chang, K. S. Kassahn, P. Bailey, A. L. Johns, D. Miller, K. Nones, K. Quek, M. C. Quinn, A. J. Robertson, M. Z. Fadlullah, T. J. C. Bruxner, A. N. Christ, I. Harliwong, S. Idrisoglu, S. Manning, C. Nourse, E. Nourbakhsh, S. Wani, P. J. Wilson, E. Markham, N. Cloonan, M. J. Anderson, J. L. Fink, O. Holmes, S. H. Kazakoff, C. Leonard, F. Newell, B. Poudel, S. Song, D. Taylor, N. Waddell, S. Wood, Q. Xu, J. Wu, M. Pinese, M. J. Cowley, H. C. Lee, M. D. Jones, A. M. Nagrial, J. Humphris, L. A. Chantrill, V. Chin, A. M. Steinmann, A. Mawson, E. S. Humphrey, E. K. Colvin, A. Chou, C. J. Scarlett, A. V. Pinho, M. Giry-Laterriere, I. Rooman, J. S. Samra, J. G. Kench, J. A. Pettitt, N. D. Merrett, C. Toon, K. Epari, N. Q. Nguyen, A. Barbour, N. Zeps, N. B. Jamieson, J. S. Graham, S. P. Niclou, R. Bjerkvig, R. Grutzmann, D. Aust, R. H. Hruban, A. Maitra, C. A. Iacobuzio-Donahue, C. L. Wolfgang, R. A. Morgan, R. T. Lawlor, V. Corbo, C. Bassi, M. Falconi, G. Zamboni, G. Tortora, M. A. Tempero; Australian Pancreatic Cancer Genome Initiative, A. J. Gill, J. R. Eshleman, C. Pilarsky, A. Scarpa, E. A. Musgrove, J. V. Pearson, A. V. Biankin, S. M. Grimmond, Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
47. S. Andrews, Fast QC A Quality Control tool for High Throughput Sequence Data (2010); http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
48. A. Dobin, C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson, T. R. Gingeras, STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
49. P. G. Engström, T. Steijger, B. Sipos, G. R. Grant, A. Kahles, G. Rätsch, N. Goldman, T. J. Hubbard, J. Harrow, R. Guigó, P. Bertone, R. Consortium, Systematic evaluation of spliced alignment programs for RNA-seq data. Nat. Methods 10, 1185-1191 (2013).
50. C. Trapnell, A. Roberts, L. Goff, G. Pertea, D. Kim, D. R. Kelley, H. Pimentel, S. L. Salzberg, J. L. Rinn, L. Pachter, Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
51. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
52. A. Liberzon, A description of the Molecular Signatures Database (MSigDB) web site. Methods Mol. Biol. 1150, 153-160 (2014).
53. S. K. Knutson, S. Kawano, Y. Minoshima, N. M. Warholic, K. C. Huang, Y. Xiao, T. Kadowaki, M. Uesugi, G. Kuznetsov, N. Kumar, T. J. Wigle, C. R. Klaus, C. J. Allain, A. Raimondi, N. J. Waters, J. J. Smith, M. Porter-Scott, R. Chesworth, M. P. Moyer, R. A. Copeland, V.M. Richon, T. Uenaka, R.M. Pollock, K. W. Kuntz, A. Yokoi, H. Keilhack, Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13, 842-854 (2014).
54. S. K. Knutson, N. M. Warholic, T. J. Wigle, C. R. Klaus, C. J. Allain, A. Raimondi, M. Porter Scott, R. Chesworth, M. P. Moyer, R. A. Copeland, V. M. Richon, R. M. Pollock, K. W. Kuntz, H. Keilhack, Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. U.S.A. 110, 7922-7927 (2013).
55. H. Schuldes, S. Bade, J. Knobloch, D. Jonas, Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures. Cancer 79, 1723-1728 (1997).
56. R. T. Kilani, Y. Tamimi, S. Karmali, J. Mackey, E. G. Hanel, K. K. Wong, R. B. Moore, Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs 13, 557-566 (2002).
57. R. M. Phillips, A. M. Burger, P. M. Loadman, C. M. Jarrett, D. J. Swaine, H.-H. Fiebig, Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development. Cancer Res. 60, 6384-6390 (2000).
58. S. Rozen, H. Skaletsky, Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365-386 (2000).
59. A. Fiser, A. Šali, Modeller: Generation and refinement of homology-based protein structure models. Methods Enzymol. 374, 461-491 (2003).
60. S. J. de Vries, M. van Dijk, A. M. J. J. Bonvin, The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5, 883-897 (2010).
61. D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, H. J. C. Berendsen, GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701-1718 (2005).
62. D. A. Case, T. E. Cheatham III, T. Darden, H. Gohlke, R. Luo, K. M. Merz Jr., A. Onufriev, C. Simmerling, B. Wang, R. J. Woods, The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668-1688 (2005).
63. C. Oostenbrink, A. Villa, A. E. Mark, W. F. Van Gunsteren, A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. Chem. 25, 1656-1676 (2004).
64. V. Hornak, R. Abel, A. Okur, B. Strockbine, A. Roitberg, C. Simmerling, Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725 (2006).
65. D. Bashford, D. A. Case, Generalized born models of macromolecular solvation effects. Annu. Rev. Phys. Chem. 51, 129-152 (2000).
66. B. R. Miller, T. D. McGee Jr., J. M. Swails, N. Homeyer, H. Gohlke, A. E. Roitberg, MMPBSA.py: An efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314-3321 (2012).
67. A. Onufriev, D. Bashford, D. A. Case, Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55, 383-394 (2004).
68. C. L. Wilson, C. J. Miller, Simpleaffy: A Bio Conductor package for Affymetrix Quality Control and data analysis. Bioinformatics 21, 3683-3685 (2005).
69. R. A. Irizarry, B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, T. P. Speed, Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
70. M. Dai, P. Wang, A. D. Boyd, G. Kostov, B. Athey, E. G. Jones, W. E. Bunney, R. M. Myers, T. P. Speed, H. Akil, S. J. Watson, F. Meng, Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005).
71. A. Meissner, T. S. Mikkelsen, H. Gu, M. Wernig, J. Hanna, A. Sivachenko, X. Zhang, B. E. Bernstein, C. Nusbaum, D. B. Jaffe, A. Gnirke, R. Jaenisch, E. S. Lander, Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766-770 (2008).
72. M. Nuytten, L. Beke, A. Van Eynde, H. Ceulemans, M. Beullens, P. Van Hummelen, F. Fuks, M. Bollen, The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Oncogene 27, 1449-1460 (2008).
73. I. Ben-Porath, M. W. Thomson, V. J. Carey, R. Ge, G. W. Bell, A. Regev, R. A. Weinberg, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008).